Neomycin, a broad-spectrum aminoglycoside antibiotic, remains a cornerstone of pharmaceutical manufacturing, veterinary medicine, and topical therapeutic formulations worldwide. As global demand for antibiotics continues to rise—driven by increasing bacterial infection rates, expanding livestock populations, and growing pharmaceutical R&D activities—understanding the landscape of neomycin buyers and suppliers has become essential for industry stakeholders. The global neomycin market is valued at approximately USD 0.95 billion as of 2024 and is projected to reach USD 1.38 billion by 2031, growing at a compound annual growth rate of 5.60%. The neomycin sulfate API segment alone was valued at USD 188 million in 2024 and is forecast to reach USD 289 million by 2031. This…